HIV-hypertension Treatment Outcomes Among Adults on Antiretroviral Therapy in Two States in Northern and Southern Nigeria: a Cross-sectional Design Approach

Overview

Journal Ther Adv Infect Dis

Publisher Sage Publications

Specialty Infectious Diseases

Date 2024 Nov 6

PMID 39502839

Authors

Oluseye Ayodele Ajayi

Deborah Babatunde

Oluwaseun Kikelomo Ajayi

Temitope Olumuyiwa Ojo

Prosper Okonkwo

Affiliations

Soon will be listed here.

Abstract

Background: The combined effect of the aging human immunodeficiency virus (HIV) population, HIV's natural progression, and HIV drugs have great implications for comorbidity burden and hypertension control among people living with HIV (PLHIV).

Objectives: This study assessed hypertension burden, treatment outcomes, and treatment outcome predictors among PLHIV in Nigeria.

Design: Cross-sectional design.

Methods: A cross-sectional study of 2613 adult PLHIV who initiated antiretroviral therapy (ART) between 2004 and 2020 in two HIV clinics in Northern and Southern Nigeria. Study outcomes were: (1) controlled blood pressure defined as two consecutive blood pressure (BP) measurements of <140/90 mmHg (Joint National Committee guideline (JNC) 7) on the interview day in previously diagnosed hypertensive participants; and (2) HIV viral suppression defined as recent viral load count of <1000 copies/ml in a hypertensive participant. Data were analyzed using Statistical Package of Social Sciences IBM version 23. Univariate and multivariate logistic regression was done to ascertain factors associated with the study outcomes at < 0.05.

Result: The mean age of respondents at the point of the study was 45.3 ± 9.8 years. Most of the participants were female, 1940 (74.2%), on a dolutegravir-based therapy, 2433 (93.2%). About 452 (17.3%) of the participants had clinically diagnosed hypertension. Of those diagnosed hypertensives, 443 (98.0%) were on antihypertensive drugs. About 407 (90.0%) and 229 (51.7%) of the hypertensive PLHIV had HIV viral suppression and controlled hypertension respectively. Factors associated with controlled hypertension were age at ART initiation (adjusted odds ratio (AOR): 0.96, 95% CI: 0.94-0.98), use of thiazide only antihypertensive (AOR: 1.91, 95% CI: 1.73-3.24, Ref: calcium channel blocker only) and thiazide-calcium channel blocker combination (AOR: 2.19, 95% CI: 1.05-4.58). No hypertension comorbidity-related factors were found to be associated with HIV viral suppression.

Conclusion: There is suboptimal hypertension control among hypertensive PLHIV especially those on non-thiazide-based antihypertensive drugs. Close monitoring should be given to hypertension management in PLHIV.

References

Manavalan P, Madut D, Hertz J, Thielman N, Okeke N, Mmbaga B . Hypertension burden and challenges across the hypertension treatment cascade among adults enrolled in HIV care in northern Tanzania. J Clin Hypertens (Greenwich). 2020; 22(8):1518-1522. PMC: 7719079. DOI: 10.1111/jch.13929. View

Kwarisiima D, Balzer L, Heller D, Kotwani P, Chamie G, Clark T . Population-Based Assessment of Hypertension Epidemiology and Risk Factors among HIV-Positive and General Populations in Rural Uganda. PLoS One. 2016; 11(5):e0156309. PMC: 4883789. DOI: 10.1371/journal.pone.0156309. View

Muddu M, Tusubira A, Sharma S, Akiteng A, Ssinabulya I, Schwartz J . Integrated Hypertension and HIV Care Cascades in an HIV Treatment Program in Eastern Uganda: A Retrospective Cohort Study. J Acquir Immune Defic Syndr. 2019; 81(5):552-561. PMC: 6625912. DOI: 10.1097/QAI.0000000000002067. View

Hoffman R, Chibwana F, Kahn D, Banda B, Phiri L, Chimombo M . High Rates of Uncontrolled Blood Pressure in Malawian Adults Living with HIV and Hypertension. Glob Heart. 2021; 16(1):81. PMC: 8663744. DOI: 10.5334/gh.1081. View

Badru O, Oduola T, Abdulrazaq A, Peter C . Prevalence and Predictive Factors of Hypertension Among People Living With HIV in Kebbi State, Nigeria: A Cross-sectional Study. J Assoc Nurses AIDS Care. 2021; 33(1):e6-e14. DOI: 10.1097/JNC.0000000000000309. View

von Elm E, Altman D, Egger M, Pocock S, Gotzsche P, Vandenbroucke J . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008; 61(4):344-9. DOI: 10.1016/j.jclinepi.2007.11.008. View

Shittu R, Odeigah L, Fakorede K, Sikiru B, Sule A, Musah Y . Prevalence and correlates of hypertension-outcome of a free medical screening in Oke-Ogun area of Oyo state, Nigeria, West Africa. J Am Soc Hypertens. 2018; 12(4):268-274. DOI: 10.1016/j.jash.2018.01.009. View

Jackson I, Lawrence S, Igwe C, Ukwe C, Okonta M . Prevalence and control of hypertension among people living with HIV receiving care at a Nigerian hospital. Pan Afr Med J. 2022; 41:153. PMC: 9058987. DOI: 10.11604/pamj.2022.41.153.21809. View

Odubela O, Odunukwe N, Peer N, Musa A, Salako B, Kengne A . Prevalence of hypertension among antiretroviral therapy naïve patients in Lagos, Nigeria. Clin Hypertens. 2023; 29(1):29. PMC: 10619289. DOI: 10.1186/s40885-023-00253-6. View

10.

Ogunmola O, Oladosu O, Olamoyegun A . Association of hypertension and obesity with HIV and antiretroviral therapy in a rural tertiary health center in Nigeria: a cross-sectional cohort study. Vasc Health Risk Manag. 2014; 10:129-37. PMC: 3964169. DOI: 10.2147/VHRM.S58449. View

11.

Rethy L, Feinstein M, Achenbach C, Townsend R, Bress A, Shah S . Antihypertensive Class and Cardiovascular Outcomes in Patients With HIV and Hypertension. Hypertension. 2021; 77(6):2023-2033. PMC: 8119362. DOI: 10.1161/HYPERTENSIONAHA.120.16263. View

12.

Costa A, Val F, Macedo A, Cubas-Vega N, Tejo P, Marques M . Increased prevalence of hypertension among people living with HIV: where to begin?. Rev Soc Bras Med Trop. 2020; 53:e20190564. PMC: 7491555. DOI: 10.1590/0037-8682-0564-2019. View

13.

So-Armah K, Benjamin L, Bloomfield G, Feinstein M, Hsue P, Njuguna B . HIV and cardiovascular disease. Lancet HIV. 2020; 7(4):e279-e293. PMC: 9346572. DOI: 10.1016/S2352-3018(20)30036-9. View

14.

. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021; 398(10304):957-980. PMC: 8446938. DOI: 10.1016/S0140-6736(21)01330-1. View

15.

Fischetti B, Sorbera M, Michael R, Njeim N . Evaluation of rates of virologic suppression in HIV-positive patients with varying numbers of comorbidities. Am J Health Syst Pharm. 2021; 79(2):72-77. DOI: 10.1093/ajhp/zxab346. View

16.

Gausi B, Berkowitz N, Jacob N, Oni T . Treatment outcomes among adults with HIV/non-communicable disease multimorbidity attending integrated care clubs in Cape Town, South Africa. AIDS Res Ther. 2021; 18(1):72. PMC: 8515722. DOI: 10.1186/s12981-021-00387-3. View

17.

Ekrikpo U, Akpan E, Ekott J, Bello A, Okpechi I, Kengne A . Prevalence and correlates of traditional risk factors for cardiovascular disease in a Nigerian ART-naive HIV population: a cross-sectional study. BMJ Open. 2018; 8(7):e019664. PMC: 6059292. DOI: 10.1136/bmjopen-2017-019664. View

18.

Xu Y, Chen X, Wang K . Global prevalence of hypertension among people living with HIV: a systematic review and meta-analysis. J Am Soc Hypertens. 2017; 11(8):530-540. DOI: 10.1016/j.jash.2017.06.004. View

19.

Autenrieth C, Beck E, Stelzle D, Mallouris C, Mahy M, Ghys P . Global and regional trends of people living with HIV aged 50 and over: Estimates and projections for 2000-2020. PLoS One. 2018; 13(11):e0207005. PMC: 6264840. DOI: 10.1371/journal.pone.0207005. View

20.

Melaku T, Chelkeba L, Mekonnen Z . Clinical care & blood pressure control among hypertensive people living with human immune deficiency virus: Prospective cohort study. Ann Med Surg (Lond). 2020; 54:114-124. PMC: 7225371. DOI: 10.1016/j.amsu.2020.04.017. View